OOIR: Observatory of International Research

Papers

(The H4-Index of Alzheimers Research & Therapy is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms	201
A novel electric field approach for improving cognitive function through ameliorating cell-specific pathology in P301S tauopathy mice	154
Genetic and clinical landscape of Chinese frontotemporal dementia: dominance of TBK1 and OPTN mutations	148
Associations of adherence to a healthy sleep pattern with the dementia risk in the UK biobank	148
Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology	136
Association between antemortem plasma and structural MRI biomarkers and postmortem tau pathology in the Mayo Clinic Study of Aging	129
Cornuside alleviates cognitive impairments induced by Aβ1−42 through attenuating NLRP3-mediated neurotoxicity by promoting mitophagy	128
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease	106
Structural brain improvements following individually tailored serious exergame-based training in mild neurocognitive disorders: exploratory randomized controlled trial	104
Longitudinal evaluation of common and unique brain-networks in variants of primary progressive aphasia	98
The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia: excess costs and associated clinical and risk factors	87
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	86
Linking oxysterols and different stages of mild cognitive impairment: insights from gut metabolites and N6-methyladenosine	85
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele	84
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease	84
Development of a Japanese polygenic risk score model for amyloid-β PET imaging in Alzheimer’s disease	82
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys	81
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease	78
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer’s prevention research cohort	78
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients	77
Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy	73
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy	72
Investigating the Aβ and tau pathology in autosomal dominant Alzheimer’s disease: insights from hybrid PET/MRI and network mapping	70
Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology	69
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis	67

Correction: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	67
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve	66
Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology	66
Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data	66
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects wi	65
Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study	64
Impact of effective connectivity within the Papez circuit on episodic memory: moderation by perivascular space function	63
Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease	59
Genome-wide association studies of Alzheimer’s disease and related disorders stratified by sex, onset age, and Apolipoprotein E genotype reveal novel risk loci in African Americans	57
Tau seeding activity in the cerebrospinal fluid of Alzheimer disease patients predicts short-term cognitive decline	57
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients	57
Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217	56
Cognitive composites for genetic frontotemporal dementia: GENFI-Cog	55
Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts	55
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC	55
CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice	54
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease	54
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease	54
Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease	53
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing	53
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort	52
Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia	52
Serum neurofilament light chain level as a predictor of cognitive stage transition	49
Mapping the long-term delayed recall-based cortex-hippocampus network constrained by the structural and functional connectome: a case-control multimodal MRI study	48
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study	48